Annual report pursuant to Section 13 and 15(d)

SEGMENT INFORMATION (Tables)

v3.19.1
SEGMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2018
Segment Reporting [Abstract]  
Schedule Of Segment Reporting Information
The following table presents information by reportable operating segment for the years ended December 31, 2018 and 2017:
 
Consumer Products
Segment
 
Specialty Pharmaceutical Segment
 
Consolidated Totals
Year ended December 31, 2018:
 

 
 

 
 

Product sales, net
$
48,244

 
$
—

 
$
48,244

 
 
 
 
 
 
Gross profit
$
33,878

 
$
—

 
$
33,878

Research and development
1,008

 
877

 
1,885

Selling, general and administrative
21,697

 
49

 
21,746

Operating income (loss)
$
11,173

 
$
(926
)
 
$
10,247

 
 
 
 
 
 
Year ended December 31, 2017:
 
 
 
 
 
Product sales, net
$
20,679

 
$
—

 
$
20,679

 
 
 
 
 
 
Gross profit
$
14,489

 
$
—

 
$
14,489

Research and development
251

 
473

 
724

Selling, general and administrative
15,957

 
236

 
16,193

Royalty buy-out
2,432

 
—

 
2,432

Operating loss
$
(4,151
)
 
$
(709
)
 
$
(4,860
)